Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Blackwell Scientific Publications Country of Publication: England NLM ID: 101300213 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1751-553X (Electronic) Linking ISSN: 17515521 NLM ISO Abbreviation: Int J Lab Hematol Subsets: MEDLINE
    • Publication Information:
      Original Publication: Oxford : Blackwell Scientific Publications, c2007-
    • Subject Terms:
      Partial Thromboplastin Time*; Antithrombins/*pharmacology ; Blood Coagulation/*drug effects ; Pipecolic Acids/*pharmacology; Antithrombins/therapeutic use ; Arginine/analogs & derivatives ; Dose-Response Relationship, Drug ; Humans ; Pipecolic Acids/therapeutic use ; Reproducibility of Results ; Sulfonamides
    • Abstract:
      Background: Argatroban is licensed for patients with heparin-induced thrombocytopenia and monitoring is conventionally by activated partial thromboplastin time (APTT) ratio with a target of 1.5-3.0 and not exceeding 100 s. The APTT may be influenced by coagulopathies, lupus anticoagulant and raised FVIII levels. Variable but not clinically significant sensitivity of APTT reagents to argatroban has been highlighted in other studies.
      Methods: Residual plasma of 15 patients (n = 124 samples) was tested on Sysmex(™) CS series using the Hemoclot(®) thrombin inhibitor assay (HTI) and APTT ratio (Actin FS and SynthASil). A subgroup from four patients (n = 31) were tested on ACL TOP(™) to compare the different platforms with the HTI. Spiked normal pooled plasma was tested with Actin FS, Actin FSL, SynthASil and APTT-SP on their respective platforms (CS5100(™) and ACL TOP(™)) to assess reagent sensitivity.
      Results: Mean concentration of argatroban by HTI assay for patient plasma was 0.47 μg/mL; the mean APTT ratio using Actin FS was 1.89 and for SynthASil 1.56. There was a poor correlation between APTT and the HTI. In the spiked normal pooled plasma, Actin FS gave a significantly higher APTT ratio than the other three reagents for the various argatroban concentrations.
      Conclusions: Hemoclot(®) thrombin inhibitor assay should be considered in patients on argatroban, particularly if there is concern the APTT may not be reflective of the degree of anticoagulation with argatroban due to other factors including coagulopathies in critically ill patients, the presence of a lupus anticoagulant or very high FVIII levels.
      (© 2015 John Wiley & Sons Ltd.)
    • Contributed Indexing:
      Keywords: Argatroban; Hemoclot thrombin inhibitor assay; activated partial thromboplastin time; heparin-induced thrombocytopenia; monitoring
    • Accession Number:
      0 (Antithrombins)
      0 (Pipecolic Acids)
      0 (Sulfonamides)
      94ZLA3W45F (Arginine)
      IY90U61Z3S (argatroban)
    • Publication Date:
      Date Created: 20150826 Date Completed: 20161013 Latest Revision: 20201209
    • Publication Date:
      20221213
    • Accession Number:
      10.1111/ijlh.12414
    • Accession Number:
      26305560